Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathleen L Miller

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Orphanet Journal of Rare Diseases|June 21, 2017
Do investors value the FDA orphan drug designation?Kathleen L Miller
Orphanet Journal of Rare Diseases|October 24, 2018
Investigating the landscape of US orphan product approvalsKathleen L Miller, Michael Lanthier
Health Affairs (Project Hope)|March 9, 2016
Trends In Orphan New Molecular Entities, 1983-2014: Half Were First In Class, And Rare Cancers Were The Most Frequent TargetKathleen L Miller, Michael Lanthier
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 27, 2017
Value Assessment in the Regulatory ContextKathleen L Miller, Janet Woodcock
Nature Reviews. Drug Discovery|January 31, 2015
Regulatory watch: Innovation in biologic new molecular entities: 1986-2014Kathleen L Miller, Michael Lanthier
Health Affairs (Project Hope)|January 8, 2024
Orphan Drug Label Expansions: Analysis Of Subsequent Rare And Common Indication ApprovalsKathleen L Miller, Michael Lanthier
Orphanet Journal of Rare Diseases|June 23, 2023
A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug ActLewis J Fermaglich, Kathleen L Miller
Contemporary Clinical Trials|April 17, 2023
The effect of the COVID-19 pandemic on US Food and Drug Administration-funded clinical trials and natural history studies for rare diseasesKathleen L Miller, Katherine I Miller Needleman
Nature Reviews. Drug Discovery|September 4, 2019
Transition probabilities for clinical trials: investigating individual diseasesKathleen L Miller, Dina Rabinovitz, Kirk W Kerr
Orphanet Journal of Rare Diseases|June 10, 2021
Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseasesKathleen L Miller, Lewis J Fermaglich, Janet Maynard
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Orphanet Journal of Rare Diseases|June 21, 2017
Do investors value the FDA orphan drug designation?Kathleen L Miller
Orphanet Journal of Rare Diseases|October 24, 2018
Investigating the landscape of US orphan product approvalsKathleen L Miller, Michael Lanthier
Health Affairs (Project Hope)|March 9, 2016
Trends In Orphan New Molecular Entities, 1983-2014: Half Were First In Class, And Rare Cancers Were The Most Frequent TargetKathleen L Miller, Michael Lanthier
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 27, 2017
Value Assessment in the Regulatory ContextKathleen L Miller, Janet Woodcock
Nature Reviews. Drug Discovery|January 31, 2015
Regulatory watch: Innovation in biologic new molecular entities: 1986-2014Kathleen L Miller, Michael Lanthier
Health Affairs (Project Hope)|January 8, 2024
Orphan Drug Label Expansions: Analysis Of Subsequent Rare And Common Indication ApprovalsKathleen L Miller, Michael Lanthier
Orphanet Journal of Rare Diseases|June 23, 2023
A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug ActLewis J Fermaglich, Kathleen L Miller
Contemporary Clinical Trials|April 17, 2023
The effect of the COVID-19 pandemic on US Food and Drug Administration-funded clinical trials and natural history studies for rare diseasesKathleen L Miller, Katherine I Miller Needleman
Nature Reviews. Drug Discovery|September 4, 2019
Transition probabilities for clinical trials: investigating individual diseasesKathleen L Miller, Dina Rabinovitz, Kirk W Kerr
Orphanet Journal of Rare Diseases|June 10, 2021
Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseasesKathleen L Miller, Lewis J Fermaglich, Janet Maynard
Pageof 4